董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven D. Harr | 男 | President, Chief Executive Officer and Director | 55 | 655.09万美元 | 未持股 | 2025-08-29 |
| Patrick Yang | 男 | Director | 77 | 未披露 | 未持股 | 2025-08-29 |
| Robert Taylor NELSEN | 男 | Director | 61 | 未披露 | 未持股 | 2025-08-29 |
| Robert L. Rosiello | 男 | Director | 67 | 未披露 | 未持股 | 2025-08-29 |
| Alise S. Reicin | 女 | Director | 64 | 45.68万美元 | 未持股 | 2025-08-29 |
| Hans Bishop | 男 | Chairman of the Board | 61 | 未披露 | 未持股 | 2025-08-29 |
| Michelle Seitz | 女 | Director | 60 | 45.68万美元 | 未持股 | 2025-08-29 |
| Richard C. Mulligan | 男 | Vice-Chairman | 70 | 190.08万美元 | 未持股 | 2025-08-29 |
| Douglas Cole | 男 | Director | 64 | 未披露 | 未持股 | 2025-08-29 |
| Joshua H. Bilenker | 男 | Director | 53 | 45.68万美元 | 未持股 | 2025-08-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven D. Harr | 男 | President, Chief Executive Officer and Director | 55 | 655.09万美元 | 未持股 | 2025-08-29 |
| Bernard J. Cassidy | 男 | Executive Vice President, General Counsel and Corporate Secretary | 70 | 未披露 | 未持股 | 2025-08-29 |
董事简历
中英对照 | 中文 | 英文- Steven D. Harr
-
Steven D. Harr是Sana的联合创始人，自2018年9月起担任Sana Biotechnology, Inc.总裁兼首席执行官，自2018年10月起担任Sana Biotechnology, Inc.董事会成员。在加入Sana之前，Harr博士曾于2014年4月至2018年3月被新基医药公司（Celgene）收购，在其任职期间曾担任Juno Therapeutics, Inc.（Juno）的首席财务官和企业发展主管，该公司是一家上市生物制药公司。在Juno，Harr博士负责公司的整体财务和运营战略。在加入Juno之前，Harr博士曾在公营跨国投资银行和金融服务公司摩根士丹利担任董事总经理兼生物技术投资银行业务主管，在担任投资银行职务之前，他在摩根士丹利担任首席生物技术研究分析师兼全球医疗保健研究联席主管。Dr. Harr此前曾担任Loxo Oncology, Inc.（LOXO）的董事会成员，该公司在Dr. Harr担任董事期间是一家上市生物制药公司，直到2019年初被礼来公司（礼来）和他共同创立的中国上市细胞治疗公司JW（Cayman）Therapeutics Co. Ltd（JW Therapeutics）收购。哈尔博士是加州大学旧金山分校的内科住院医师。哈尔博士在约翰霍普金斯大学医学院获得医学博士学位，在圣十字学院获得经济学学士学位。
Steven D. Harr,is a co-founder of Sana and has served as Sana Biotechnology, Inc. President and Chief Executive Officer since September 2018 and as a member of Sana Biotechnology, Inc. Board since October 2018. Prior to Sana, Dr. Harr served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, Inc. (Juno), which was a public biopharmaceutical company during his tenure, from April 2014 until its acquisition by Celgene Corporation (Celgene) in March 2018. At Juno, Dr. Harr was responsible for the overall financial and operational strategy of the company. Prior to Juno, Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley, a public multinational investment bank and financial services company, and prior to his investment banking role was the Lead Biotech Research Analyst and Co-head of Global Healthcare Research at Morgan Stanley. Dr. Harr previously served as a member of the boards of directors of Loxo Oncology, Inc. (Loxo), which was a public biopharmaceutical company during Dr. Harr's service as a director, until its acquisition by Eli Lilly and Company (Eli Lilly) in early 2019, and JW (Cayman) Therapeutics Co. Ltd (JW Therapeutics), a public cell therapy company in China that he co-founded. Dr. Harr was a resident in internal medicine at the University of California, San Francisco. Dr. Harr received his M.D. from the Johns Hopkins University School of Medicine and his B.A. in Economics from the College of the Holy Cross. - Steven D. Harr是Sana的联合创始人，自2018年9月起担任Sana Biotechnology, Inc.总裁兼首席执行官，自2018年10月起担任Sana Biotechnology, Inc.董事会成员。在加入Sana之前，Harr博士曾于2014年4月至2018年3月被新基医药公司（Celgene）收购，在其任职期间曾担任Juno Therapeutics, Inc.（Juno）的首席财务官和企业发展主管，该公司是一家上市生物制药公司。在Juno，Harr博士负责公司的整体财务和运营战略。在加入Juno之前，Harr博士曾在公营跨国投资银行和金融服务公司摩根士丹利担任董事总经理兼生物技术投资银行业务主管，在担任投资银行职务之前，他在摩根士丹利担任首席生物技术研究分析师兼全球医疗保健研究联席主管。Dr. Harr此前曾担任Loxo Oncology, Inc.（LOXO）的董事会成员，该公司在Dr. Harr担任董事期间是一家上市生物制药公司，直到2019年初被礼来公司（礼来）和他共同创立的中国上市细胞治疗公司JW（Cayman）Therapeutics Co. Ltd（JW Therapeutics）收购。哈尔博士是加州大学旧金山分校的内科住院医师。哈尔博士在约翰霍普金斯大学医学院获得医学博士学位，在圣十字学院获得经济学学士学位。
- Steven D. Harr,is a co-founder of Sana and has served as Sana Biotechnology, Inc. President and Chief Executive Officer since September 2018 and as a member of Sana Biotechnology, Inc. Board since October 2018. Prior to Sana, Dr. Harr served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, Inc. (Juno), which was a public biopharmaceutical company during his tenure, from April 2014 until its acquisition by Celgene Corporation (Celgene) in March 2018. At Juno, Dr. Harr was responsible for the overall financial and operational strategy of the company. Prior to Juno, Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley, a public multinational investment bank and financial services company, and prior to his investment banking role was the Lead Biotech Research Analyst and Co-head of Global Healthcare Research at Morgan Stanley. Dr. Harr previously served as a member of the boards of directors of Loxo Oncology, Inc. (Loxo), which was a public biopharmaceutical company during Dr. Harr's service as a director, until its acquisition by Eli Lilly and Company (Eli Lilly) in early 2019, and JW (Cayman) Therapeutics Co. Ltd (JW Therapeutics), a public cell therapy company in China that he co-founded. Dr. Harr was a resident in internal medicine at the University of California, San Francisco. Dr. Harr received his M.D. from the Johns Hopkins University School of Medicine and his B.A. in Economics from the College of the Holy Cross.
- Patrick Yang
-
Patrick Yang，是一家私营生物制造技术公司National Resilience，Inc.的联合创始人和副董事长，Acepodia，Inc.（Acepodia）的联合创始人，Acepodia是一家位于台湾的公立临床阶段生物技术公司，也是一家私营生物制药制造公司台湾生物制造公司（TBMC）的董事长。杨博士于2017年9月至2019年1月担任Juno执行副总裁。自2013年起，杨博士担任生物技术和生物制药行业顾问。2010年1月至2013年3月，杨博士在医疗保健公司F. Hoffmann-La Roche Ltd.（罗氏）担任执行副总裁兼技术运营全球主管，负责该公司的制药工艺开发、工程、质量、技术监管、供应链和制造工厂。在加入罗氏公司之前，杨博士曾在生物技术公司基因泰克、上市制药公司默克制药公司（默沙东）、上市工业公司通用电气公司以及生命科学研发公司Life Systems，Inc.担任越来越重要的职务，在此期间，他在制药和生物技术制造、工程、技术和供应链管理方面积累了丰富的经验。杨博士目前担任Acepodia和TBMC的董事会成员。杨博士此前曾在上市生物技术公司Amyris, Inc.、上市独立石油提炼和营销公司Andeavor，Inc.（前身为Tesoro Corporation）、上市生物技术公司Codexis, Inc.、台湾上市生物制药公司PharmaEssentia Corp.和台湾上市生物技术公司Polaris Group的董事会任职。杨博士于美国俄亥俄州立大学获得工学博士学位，于美国辛辛那提大学获得电机工程学硕士学位，于台湾国立交通大学获得工学学士学位。
Patrick Yang,is a co-founder and Vice Chairman of National Resilience, Inc., a privately held biomanufacturing technology company, a co-founder of Acepodia, Inc. (Acepodia), a public clinical-stage biotechnology company based in Taiwan, and the Chairman of Taiwan Bio-Manufacturing Corporation (TBMC), a privately held biopharmaceutical manufacturing company. Dr. Yang served as Executive Vice President at Juno from September 2017 to January 2019. Since 2013, Dr. Yang has served as a biotechnology and biopharmaceutical industry consultant. From January 2010 to March 2013, Dr. Yang served as Executive Vice President and Global Head of Technical Operations at F. Hoffmann-La Roche Ltd. (Roche), a healthcare company, where he was responsible for the company's pharmaceutical process development, engineering, quality, technical regulatory, supply chain, and manufacturing plants. Before joining Roche, Dr. Yang served in roles of increasing responsibility at each of Genentech, Inc., a biotechnology company, Merck & Co., Inc. (Merck), a public pharmaceutical company, General Electric Company, a public industrial company, and Life Systems, Inc., a life science research and development company, during which time he developed significant experience with pharmaceuticals and biotechnology manufacturing, engineering, technology, and supply chain management. Dr. Yang currently serves on the boards of directors of Acepodia and TBMC. Dr. Yang previously served on the boards of directors of Amyris, Inc., a public biotechnology company, Andeavor, Inc. (formerly Tesoro Corporation), a public independent petroleum refining and marketing company, Codexis, Inc., a public biotechnology company, PharmaEssentia Corp., a public biopharmaceutical company based in Taiwan, and Polaris Group, a public biotechnology company based in Taiwan. Dr. Yang received his Ph.D. in Engineering from the Ohio State University, his M.Sc. in Electrical Engineering from the University of Cincinnati, and his B.S. in Engineering from the National Chiaotung University in Taiwan. - Patrick Yang，是一家私营生物制造技术公司National Resilience，Inc.的联合创始人和副董事长，Acepodia，Inc.（Acepodia）的联合创始人，Acepodia是一家位于台湾的公立临床阶段生物技术公司，也是一家私营生物制药制造公司台湾生物制造公司（TBMC）的董事长。杨博士于2017年9月至2019年1月担任Juno执行副总裁。自2013年起，杨博士担任生物技术和生物制药行业顾问。2010年1月至2013年3月，杨博士在医疗保健公司F. Hoffmann-La Roche Ltd.（罗氏）担任执行副总裁兼技术运营全球主管，负责该公司的制药工艺开发、工程、质量、技术监管、供应链和制造工厂。在加入罗氏公司之前，杨博士曾在生物技术公司基因泰克、上市制药公司默克制药公司（默沙东）、上市工业公司通用电气公司以及生命科学研发公司Life Systems，Inc.担任越来越重要的职务，在此期间，他在制药和生物技术制造、工程、技术和供应链管理方面积累了丰富的经验。杨博士目前担任Acepodia和TBMC的董事会成员。杨博士此前曾在上市生物技术公司Amyris, Inc.、上市独立石油提炼和营销公司Andeavor，Inc.（前身为Tesoro Corporation）、上市生物技术公司Codexis, Inc.、台湾上市生物制药公司PharmaEssentia Corp.和台湾上市生物技术公司Polaris Group的董事会任职。杨博士于美国俄亥俄州立大学获得工学博士学位，于美国辛辛那提大学获得电机工程学硕士学位，于台湾国立交通大学获得工学学士学位。
- Patrick Yang,is a co-founder and Vice Chairman of National Resilience, Inc., a privately held biomanufacturing technology company, a co-founder of Acepodia, Inc. (Acepodia), a public clinical-stage biotechnology company based in Taiwan, and the Chairman of Taiwan Bio-Manufacturing Corporation (TBMC), a privately held biopharmaceutical manufacturing company. Dr. Yang served as Executive Vice President at Juno from September 2017 to January 2019. Since 2013, Dr. Yang has served as a biotechnology and biopharmaceutical industry consultant. From January 2010 to March 2013, Dr. Yang served as Executive Vice President and Global Head of Technical Operations at F. Hoffmann-La Roche Ltd. (Roche), a healthcare company, where he was responsible for the company's pharmaceutical process development, engineering, quality, technical regulatory, supply chain, and manufacturing plants. Before joining Roche, Dr. Yang served in roles of increasing responsibility at each of Genentech, Inc., a biotechnology company, Merck & Co., Inc. (Merck), a public pharmaceutical company, General Electric Company, a public industrial company, and Life Systems, Inc., a life science research and development company, during which time he developed significant experience with pharmaceuticals and biotechnology manufacturing, engineering, technology, and supply chain management. Dr. Yang currently serves on the boards of directors of Acepodia and TBMC. Dr. Yang previously served on the boards of directors of Amyris, Inc., a public biotechnology company, Andeavor, Inc. (formerly Tesoro Corporation), a public independent petroleum refining and marketing company, Codexis, Inc., a public biotechnology company, PharmaEssentia Corp., a public biopharmaceutical company based in Taiwan, and Polaris Group, a public biotechnology company based in Taiwan. Dr. Yang received his Ph.D. in Engineering from the Ohio State University, his M.Sc. in Electrical Engineering from the University of Cincinnati, and his B.S. in Engineering from the National Chiaotung University in Taiwan.
- Robert Taylor NELSEN
-
Robert Taylor NELSEN自2020年9月起担任Prime Medicine， Inc.董事会成员，根据ARCH在Prime Medicine， Inc.下任命Prime Medicine， Inc.董事会代表的权利。投票协议，日期截至2019年9月26日，与Prime Medicine， Inc.有关。A系列优先股融资，于2021年4月20日修订并重述与Prime Medicine， Inc.有关。B轮优先股融资。他于1986年共同创立了ARCH Venture Partners， l.p.（一家专注于早期技术公司的风险资公司），并自1994年以来担任ARCH Venture Partners或其附属实体的董事总经理。他目前担任Brii Biosciences Limited、Denali Therapeutics Inc.、Vir Biotechnology, Inc.、Sana Biotechnology, Inc.、Lyell Immunopharma, Inc.、Revolution Healthcare Acquisition Corp.和Hua Medicine， Inc.（每个上市生物技术公司）的董事会成员，目前担任许多私人公司的董事会成员。Taylor先生此前曾担任多家上市生物技术公司的董事会成员，包括Unity biotechnology， Inc.（2015年至2020年12月）Agios Pharmaceuticals, Inc.（2007年至2017年6月）Syros Pharmaceuticals, Inc.（2012年至2018年6月）Juno Therapeutics, Inc.（2013年1月至2018年3月）被Celgene Corporation收购；从2017年到2018年12月（首次公开发行之前）。他持有Chicago大学的工商管理硕士学位，以及Puget Sound大学的经济学和生物学学士学位。
Robert Taylor NELSEN,is a co-founder and has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 1994, and has played a significant role in the early sourcing, financing, and development of more than 150 biopharmaceutical companies. Mr. Nelsen currently serves on the boards of directors of several public biotechnology, biopharmaceutical, and healthcare companies, including Hua Medicine, where he serves as Chairman, Lyell Immunopharma, Prime Medicine, Inc., and Vir Biotechnology, Inc. Mr. Nelsen previously served on the boards of directors of several public biotechnology and biopharmaceutical companies, including Adolor Corporation, Agios Pharmaceuticals, Inc., Beam Therapeutics Inc. (Beam), Bellerophon Therapeutics, Inc., Brii Biosciences Limited, Denali, Fate Therapeutics, Inc., Gossamer Bio, Inc. (Gossamer Bio), Illumina, Juno, Karuna Therapeutics, Inc., KYTHERA Biopharmaceuticals, Inc., NeurogesX, Inc., Revolution Healthcare Acquisition Corp., Sage Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Syros Pharmaceuticals, Inc., and Unity Biotechnology, Inc. He also previously served as a Trustee of the Fred Hutchinson Cancer Center and the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the University of Chicago Booth School of Business and his B.S. in Economics and Biology from the University of Puget Sound. - Robert Taylor NELSEN自2020年9月起担任Prime Medicine， Inc.董事会成员，根据ARCH在Prime Medicine， Inc.下任命Prime Medicine， Inc.董事会代表的权利。投票协议，日期截至2019年9月26日，与Prime Medicine， Inc.有关。A系列优先股融资，于2021年4月20日修订并重述与Prime Medicine， Inc.有关。B轮优先股融资。他于1986年共同创立了ARCH Venture Partners， l.p.（一家专注于早期技术公司的风险资公司），并自1994年以来担任ARCH Venture Partners或其附属实体的董事总经理。他目前担任Brii Biosciences Limited、Denali Therapeutics Inc.、Vir Biotechnology, Inc.、Sana Biotechnology, Inc.、Lyell Immunopharma, Inc.、Revolution Healthcare Acquisition Corp.和Hua Medicine， Inc.（每个上市生物技术公司）的董事会成员，目前担任许多私人公司的董事会成员。Taylor先生此前曾担任多家上市生物技术公司的董事会成员，包括Unity biotechnology， Inc.（2015年至2020年12月）Agios Pharmaceuticals, Inc.（2007年至2017年6月）Syros Pharmaceuticals, Inc.（2012年至2018年6月）Juno Therapeutics, Inc.（2013年1月至2018年3月）被Celgene Corporation收购；从2017年到2018年12月（首次公开发行之前）。他持有Chicago大学的工商管理硕士学位，以及Puget Sound大学的经济学和生物学学士学位。
- Robert Taylor NELSEN,is a co-founder and has served as Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, since 1994, and has played a significant role in the early sourcing, financing, and development of more than 150 biopharmaceutical companies. Mr. Nelsen currently serves on the boards of directors of several public biotechnology, biopharmaceutical, and healthcare companies, including Hua Medicine, where he serves as Chairman, Lyell Immunopharma, Prime Medicine, Inc., and Vir Biotechnology, Inc. Mr. Nelsen previously served on the boards of directors of several public biotechnology and biopharmaceutical companies, including Adolor Corporation, Agios Pharmaceuticals, Inc., Beam Therapeutics Inc. (Beam), Bellerophon Therapeutics, Inc., Brii Biosciences Limited, Denali, Fate Therapeutics, Inc., Gossamer Bio, Inc. (Gossamer Bio), Illumina, Juno, Karuna Therapeutics, Inc., KYTHERA Biopharmaceuticals, Inc., NeurogesX, Inc., Revolution Healthcare Acquisition Corp., Sage Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Syros Pharmaceuticals, Inc., and Unity Biotechnology, Inc. He also previously served as a Trustee of the Fred Hutchinson Cancer Center and the Institute for Systems Biology, and as a director of the National Venture Capital Association. Mr. Nelsen received his M.B.A. from the University of Chicago Booth School of Business and his B.S. in Economics and Biology from the University of Puget Sound.
- Robert L. Rosiello
-
Robert L. Rosiello，2015年6月11日加入公司担任执行副总裁，自2015年7月1日起担任执行副总裁兼首席财务官；自2015年12月28日起成为三名首席执行官之一，彼时Pearson先生因医疗假期离开，直至2016年1月6日任命临时首席执行官。在加入公司之前，他在McKinsey & Company任职30年，通过并购和业务单元财务业绩改善，协助医疗保健技术和定制企业扩大增长。作为负责全球合并活动逾10年的高级合伙人，他领导了美国、欧洲和亚洲的制药、特殊制药和医疗器械企业的并购事务。他目前是Catholic Charities of New York和the Central Selection Committee of the Morehead Cain Foundation的董事，曾担任the Pew Research Center的董事。他获得了the University of North Carolina的经济学学士学位，是一名Morehead学者，也获得了the London School of Economics的硕士学位，和Harvard的工商管理硕士学位。
Robert L. Rosiello joined the Company as Executive Vice President on June 11 2015 and has been our Executive Vice President and Chief Financial Officer since July 1 2015. Commencing December 28 2015 he served as one of the three members of the Office of the Chief Executive Officer, while Mr. Pearson was on medical leave until an Interim CEO was appointed by the Board on January 6 2016. Prior to joining the Company, he worked for 30 years at McKinsey & Company, helping healthcare technology and consumer companies deliver growth through mergers and acquisitions, as well as business unit financial performance improvement. As Senior Partner in charge of the global merger practice for a decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S., Europe and Asia. He serves on the Board of Catholic Charities of New York and the Central Selection Committee of the Morehead Cain Foundation and previously served on the board of the Pew Research Center. Mr. Rosiello received his BA in economics from the University of North Carolina, where he was a Morehead Scholar. He also earned an MS from the London School of Economics and an MBA from Harvard. - Robert L. Rosiello，2015年6月11日加入公司担任执行副总裁，自2015年7月1日起担任执行副总裁兼首席财务官；自2015年12月28日起成为三名首席执行官之一，彼时Pearson先生因医疗假期离开，直至2016年1月6日任命临时首席执行官。在加入公司之前，他在McKinsey & Company任职30年，通过并购和业务单元财务业绩改善，协助医疗保健技术和定制企业扩大增长。作为负责全球合并活动逾10年的高级合伙人，他领导了美国、欧洲和亚洲的制药、特殊制药和医疗器械企业的并购事务。他目前是Catholic Charities of New York和the Central Selection Committee of the Morehead Cain Foundation的董事，曾担任the Pew Research Center的董事。他获得了the University of North Carolina的经济学学士学位，是一名Morehead学者，也获得了the London School of Economics的硕士学位，和Harvard的工商管理硕士学位。
- Robert L. Rosiello joined the Company as Executive Vice President on June 11 2015 and has been our Executive Vice President and Chief Financial Officer since July 1 2015. Commencing December 28 2015 he served as one of the three members of the Office of the Chief Executive Officer, while Mr. Pearson was on medical leave until an Interim CEO was appointed by the Board on January 6 2016. Prior to joining the Company, he worked for 30 years at McKinsey & Company, helping healthcare technology and consumer companies deliver growth through mergers and acquisitions, as well as business unit financial performance improvement. As Senior Partner in charge of the global merger practice for a decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S., Europe and Asia. He serves on the Board of Catholic Charities of New York and the Central Selection Committee of the Morehead Cain Foundation and previously served on the board of the Pew Research Center. Mr. Rosiello received his BA in economics from the University of North Carolina, where he was a Morehead Scholar. He also earned an MS from the London School of Economics and an MBA from Harvard.
- Alise S. Reicin
-
AliseS.Reicin自2020年12月起担任董事会成员。Reicin博士自2020年8月起担任生物技术公司Structural Therapeutic，Inc.的首席执行官兼总裁。在加入Structural Therapeutic之前，她曾于2018年11月至2019年12月担任上市制药公司新基医药公司全球临床开发总裁。在Celgene之前，她曾于2015年5月至2018年10月担任制药公司EMD Serono的全球临床开发主管，在此之前，她曾担任上市制药公司默克公司（Merck and Co.）的肿瘤学Vice President，项目和管道领导。任职Merck公司之前，她曾担任Columbia Medical School的教员，以及Columbia Presbyterian Hospital的医生兼研究员。Reicin博士是HomologyMedicines，Inc.公司（一家上市的临床阶段生物制药公司）的董事会成员。Reicin博士在哈佛医学院（Harvard Medical School）获得医学博士学位，在哥伦比亚大学巴纳德学院（Barnard College of Columbia University）获得生物化学学士学位。
Alise S. Reicin,has served as President and Chief Executive Officer of Tectonic Therapeutic, Inc. (Tectonic), a public biotechnology company, since August 2020. Prior to Tectonic, she served as President, Global Clinical Development at Celgene, which was a public biopharmaceutical company, from November 2018 to December 2019. Prior to Celgene, she served as Head of Global Clinical Development at EMD Serono Inc. (EMD Serono), a privately held pharmaceutical company, from May 2015 to October 2018. Prior to EMD Serono, Dr. Reicin served as Vice President, Program and Pipeline Leadership, Oncology at Merck. Prior to Merck, she was a faculty member at Columbia Medical School and a physician and researcher at Columbia Presbyterian Hospital. Dr. Reicin currently serves on the boards of directors of Immatics N.V., a public biopharmaceutical company based in Germany, and Tectonic. Dr. Reicin previously served on the board of directors of Homology Medicines, Inc., which was a public biopharmaceutical company during Dr. Reicin's service as a director. Dr. Reicin received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University. - AliseS.Reicin自2020年12月起担任董事会成员。Reicin博士自2020年8月起担任生物技术公司Structural Therapeutic，Inc.的首席执行官兼总裁。在加入Structural Therapeutic之前，她曾于2018年11月至2019年12月担任上市制药公司新基医药公司全球临床开发总裁。在Celgene之前，她曾于2015年5月至2018年10月担任制药公司EMD Serono的全球临床开发主管，在此之前，她曾担任上市制药公司默克公司（Merck and Co.）的肿瘤学Vice President，项目和管道领导。任职Merck公司之前，她曾担任Columbia Medical School的教员，以及Columbia Presbyterian Hospital的医生兼研究员。Reicin博士是HomologyMedicines，Inc.公司（一家上市的临床阶段生物制药公司）的董事会成员。Reicin博士在哈佛医学院（Harvard Medical School）获得医学博士学位，在哥伦比亚大学巴纳德学院（Barnard College of Columbia University）获得生物化学学士学位。
- Alise S. Reicin,has served as President and Chief Executive Officer of Tectonic Therapeutic, Inc. (Tectonic), a public biotechnology company, since August 2020. Prior to Tectonic, she served as President, Global Clinical Development at Celgene, which was a public biopharmaceutical company, from November 2018 to December 2019. Prior to Celgene, she served as Head of Global Clinical Development at EMD Serono Inc. (EMD Serono), a privately held pharmaceutical company, from May 2015 to October 2018. Prior to EMD Serono, Dr. Reicin served as Vice President, Program and Pipeline Leadership, Oncology at Merck. Prior to Merck, she was a faculty member at Columbia Medical School and a physician and researcher at Columbia Presbyterian Hospital. Dr. Reicin currently serves on the boards of directors of Immatics N.V., a public biopharmaceutical company based in Germany, and Tectonic. Dr. Reicin previously served on the board of directors of Homology Medicines, Inc., which was a public biopharmaceutical company during Dr. Reicin's service as a director. Dr. Reicin received her M.D. from Harvard Medical School and her B.A. in Biochemistry from Barnard College of Columbia University.
- Hans Bishop
-
Hans Bishop自2018年8月起担任Lyell Immunopharma, Inc.的董事会成员。自2019年起，Bishop先生担任GRAIL，Inc.的首席执行官，GRAIL，Inc.是一家私营生命科学公司。2013年7月至2018年3月，毕晓普先生担任Juno Therapeutics的总裁兼首席执行官，这是一家由他创立并被Celgene收购的公司。2012年2月至2013年7月，毕晓普先生在华平（一家跨国私人股本公司）担任常驻高管。2010年1月至2011年9月，毕晓普先生在上市癌症免疫治疗公司Dendreon，Inc.担任执行副总裁兼首席运营官。2006年12月至2010年1月，毕晓普先生在上市公司拜耳医疗保健公司（Bayer Healthcare）担任专业医药总裁。2004年1月至2006年8月，他在跨国生物技术公司凯龙公司担任多个领导职位，包括全球商业运营高级副总裁和欧洲生物制药副总裁兼总经理。他目前自2018年10月起担任萨那生物科技公司董事长，自2017年7月起担任安捷伦科技公司和JW Therapeutics公司董事，这两家公司均为上市公司，曾于2018年6月至2019年11月任CELGEN主任，主教先生在伦敦布鲁内尔大学获化学学士学位。
Hans Bishop has served as a member of our board of directors since August 2018. Since 2019 Mr. Bishop has served as the Chief Executive Officer of GRAIL, Inc., a private life sciences company. From July 2013 to March 2018 Mr. Bishop served as President and Chief Executive Officer at Juno Therapeutics, a company that he founded and that was acquired by Celgene. From February 2012 through July 2013 Mr. Bishop served as Executive in Residence at Warburg Pincus, a multinational private equity firm. From January 2010 to September 2011 Mr. Bishop served as Executive Vice President and Chief Operating Officer at Dendreon, Inc., a publicly-traded cancer immunotherapy company. From December 2006 to January 2010 Mr. Bishop served as President of Specialty Medicine at Bayer Healthcare, a publicly-traded company. From January 2004 to August 2006 he served in multiple leadership positions at Chiron Corporation, a multinational biotechnology company, including as Senior Vice President of Global Commercial Operations and Vice President and General Manager of European Biopharmaceuticals. He currently serves as the Chairman of Sana Biotechnology since October 2018 and as a director of Agilent Technologies since July 2017 and JW Therapeutics, all of which are publicly-traded companies, and previously served as a director of Celgene from June 2018 to November 2019. Mr. Bishop received a B.A. in Chemistry from Brunel University in London. - Hans Bishop自2018年8月起担任Lyell Immunopharma, Inc.的董事会成员。自2019年起，Bishop先生担任GRAIL，Inc.的首席执行官，GRAIL，Inc.是一家私营生命科学公司。2013年7月至2018年3月，毕晓普先生担任Juno Therapeutics的总裁兼首席执行官，这是一家由他创立并被Celgene收购的公司。2012年2月至2013年7月，毕晓普先生在华平（一家跨国私人股本公司）担任常驻高管。2010年1月至2011年9月，毕晓普先生在上市癌症免疫治疗公司Dendreon，Inc.担任执行副总裁兼首席运营官。2006年12月至2010年1月，毕晓普先生在上市公司拜耳医疗保健公司（Bayer Healthcare）担任专业医药总裁。2004年1月至2006年8月，他在跨国生物技术公司凯龙公司担任多个领导职位，包括全球商业运营高级副总裁和欧洲生物制药副总裁兼总经理。他目前自2018年10月起担任萨那生物科技公司董事长，自2017年7月起担任安捷伦科技公司和JW Therapeutics公司董事，这两家公司均为上市公司，曾于2018年6月至2019年11月任CELGEN主任，主教先生在伦敦布鲁内尔大学获化学学士学位。
- Hans Bishop has served as a member of our board of directors since August 2018. Since 2019 Mr. Bishop has served as the Chief Executive Officer of GRAIL, Inc., a private life sciences company. From July 2013 to March 2018 Mr. Bishop served as President and Chief Executive Officer at Juno Therapeutics, a company that he founded and that was acquired by Celgene. From February 2012 through July 2013 Mr. Bishop served as Executive in Residence at Warburg Pincus, a multinational private equity firm. From January 2010 to September 2011 Mr. Bishop served as Executive Vice President and Chief Operating Officer at Dendreon, Inc., a publicly-traded cancer immunotherapy company. From December 2006 to January 2010 Mr. Bishop served as President of Specialty Medicine at Bayer Healthcare, a publicly-traded company. From January 2004 to August 2006 he served in multiple leadership positions at Chiron Corporation, a multinational biotechnology company, including as Senior Vice President of Global Commercial Operations and Vice President and General Manager of European Biopharmaceuticals. He currently serves as the Chairman of Sana Biotechnology since October 2018 and as a director of Agilent Technologies since July 2017 and JW Therapeutics, all of which are publicly-traded companies, and previously served as a director of Celgene from June 2018 to November 2019. Mr. Bishop received a B.A. in Chemistry from Brunel University in London.
- Michelle Seitz
-
Michelle Seitz，现任MeydenVest Partners创始人兼首席执行官，自2022年9月起担任该职务。在MeydenVest Partners之前，Seitz女士曾于2017年9月至2022年10月在Russell Investments担任首席执行官，并于2018年1月至2022年9月担任董事会主席。在加入罗素投资之前，Seitz女士于1996年2月至2017年8月在William Blair担任多个高级职位，最近担任William Blair Investment Management首席执行官、William Blair Funds主席兼总裁，并于2001年6月至2017年8月担任董事会成员。Seitz女士自2020年11月起担任Sana Biotechnology, Inc.（NASDAQ：SANA）的董事，并自2020年12月起担任其审计委员会成员。Seitz女士拥有印第安纳大学凯利商学院会计学理学学士学位，并且是一名特许金融分析师（CFA）。
Michelle Seitz,has served as a member of Sana Biotechnology, Inc. Board since November 2020. Ms. Seitz founded MeydenVest Partners, a private investment and strategic advisory firm, and has served as its Chief Executive Officer since September 2022. Ms. Seitz served at Russell Investments, a privately held global investment solutions provider, as Chief Executive Officer from September 2017 to October 2022, and as Chairman of the Board from January 2018 to September 2022. Prior to Russell Investments, Ms. Seitz held various positions at William Blair, a global investment banking and wealth management firm, from February 1996 to August 2017, most recently serving as the Chief Executive Officer of William Blair Investment Management, Chair and President of William Blair Funds, and as a member of the board of directors from June 2001 to August 2017. Ms. Seitz currently serves on the boards of directors of MSCI, Inc., a public financial services company, and the Fred Hutchinson Cancer Center, and on the Dean's Council at the Indiana University Kelley School of Business. Ms. Seitz previously served as a director of the Financial Accounting Foundation, which provides oversight of Financial Accounting Standards Board (FASB) and Governmental Accounting Standards Board, and as Co-Chair of Challenge Seattle, an alliance of chief executive officers of multinational companies within the Seattle region. Ms. Seitz received her B.S. in Accounting from the Indiana University Kelley School of Business and her Chartered Financial Analyst designation. - Michelle Seitz，现任MeydenVest Partners创始人兼首席执行官，自2022年9月起担任该职务。在MeydenVest Partners之前，Seitz女士曾于2017年9月至2022年10月在Russell Investments担任首席执行官，并于2018年1月至2022年9月担任董事会主席。在加入罗素投资之前，Seitz女士于1996年2月至2017年8月在William Blair担任多个高级职位，最近担任William Blair Investment Management首席执行官、William Blair Funds主席兼总裁，并于2001年6月至2017年8月担任董事会成员。Seitz女士自2020年11月起担任Sana Biotechnology, Inc.（NASDAQ：SANA）的董事，并自2020年12月起担任其审计委员会成员。Seitz女士拥有印第安纳大学凯利商学院会计学理学学士学位，并且是一名特许金融分析师（CFA）。
- Michelle Seitz,has served as a member of Sana Biotechnology, Inc. Board since November 2020. Ms. Seitz founded MeydenVest Partners, a private investment and strategic advisory firm, and has served as its Chief Executive Officer since September 2022. Ms. Seitz served at Russell Investments, a privately held global investment solutions provider, as Chief Executive Officer from September 2017 to October 2022, and as Chairman of the Board from January 2018 to September 2022. Prior to Russell Investments, Ms. Seitz held various positions at William Blair, a global investment banking and wealth management firm, from February 1996 to August 2017, most recently serving as the Chief Executive Officer of William Blair Investment Management, Chair and President of William Blair Funds, and as a member of the board of directors from June 2001 to August 2017. Ms. Seitz currently serves on the boards of directors of MSCI, Inc., a public financial services company, and the Fred Hutchinson Cancer Center, and on the Dean's Council at the Indiana University Kelley School of Business. Ms. Seitz previously served as a director of the Financial Accounting Foundation, which provides oversight of Financial Accounting Standards Board (FASB) and Governmental Accounting Standards Board, and as Co-Chair of Challenge Seattle, an alliance of chief executive officers of multinational companies within the Seattle region. Ms. Seitz received her B.S. in Accounting from the Indiana University Kelley School of Business and her Chartered Financial Analyst designation.
- Richard C. Mulligan
-
Richard C. Mulligan，他是Sarissa Capital Management LP的创始合伙人， 该公司是成立于2012年的注册投资顾问公司。Sarissa Capital注重于提高公司战略，为股东提供更佳的价值。2013年，他成为哈佛医学院（Harvard Medical School）的荣誉遗传学马林克罗特教授，1996年起，担任遗传学马林克罗特教授和Harvard Gene Therapy Initiative的董事。在此之前，他是麻省理工学院（Massachusetts Institute of Technology）的分析生物学教授、Whitehead Institute for Biomedical Research的成员和Somatix Therapy Corporation的首席科技官， 该公司是他成立的药物开发公司。1981年，他被评为麦克阿瑟基金会会员。过去5年内，他担任医疗保健公司Cellectis SA, Enzon Pharmaceuticals, Inc.和ImClone Systems Incorporated的董事。
Richard C. Mulligan,served in various roles, most recently as Head of Sana Innovation Research, until March 2024. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School (Harvard), and served as Visiting Scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) from March 2017 to February 2021. From March 2017 to October 2018, Dr. Mulligan served as Portfolio Manager at Icahn Capital LP, an investment management firm, and from May 2013 to December 2016, he served as Founding Partner and Senior Managing Director of Sarissa Capital Management LP, a registered investment advisor. From 1996 to 2013, Dr. Mulligan served as the Mallinckrodt Professor of Genetics at Harvard and Director of the Harvard Gene Therapy Initiative. Prior to that, he served as Professor of Molecular Biology at MIT and a member of the Whitehead Institute for Biomedical Research. Dr. Mulligan currently serves on the board of directors of Bausch Health Companies Inc., a public pharmaceutical company. Dr. Mulligan previously served on the board of directors of Biogen Inc., a public biotechnology company. Dr. Mulligan's honors include the MacArthur Foundation Genius Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize. Dr. Mulligan received his Ph.D. in Biochemistry from the Stanford University School of Medicine and his B.S. from MIT. - Richard C. Mulligan，他是Sarissa Capital Management LP的创始合伙人， 该公司是成立于2012年的注册投资顾问公司。Sarissa Capital注重于提高公司战略，为股东提供更佳的价值。2013年，他成为哈佛医学院（Harvard Medical School）的荣誉遗传学马林克罗特教授，1996年起，担任遗传学马林克罗特教授和Harvard Gene Therapy Initiative的董事。在此之前，他是麻省理工学院（Massachusetts Institute of Technology）的分析生物学教授、Whitehead Institute for Biomedical Research的成员和Somatix Therapy Corporation的首席科技官， 该公司是他成立的药物开发公司。1981年，他被评为麦克阿瑟基金会会员。过去5年内，他担任医疗保健公司Cellectis SA, Enzon Pharmaceuticals, Inc.和ImClone Systems Incorporated的董事。
- Richard C. Mulligan,served in various roles, most recently as Head of Sana Innovation Research, until March 2024. Dr. Mulligan is currently the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School (Harvard), and served as Visiting Scientist at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT) from March 2017 to February 2021. From March 2017 to October 2018, Dr. Mulligan served as Portfolio Manager at Icahn Capital LP, an investment management firm, and from May 2013 to December 2016, he served as Founding Partner and Senior Managing Director of Sarissa Capital Management LP, a registered investment advisor. From 1996 to 2013, Dr. Mulligan served as the Mallinckrodt Professor of Genetics at Harvard and Director of the Harvard Gene Therapy Initiative. Prior to that, he served as Professor of Molecular Biology at MIT and a member of the Whitehead Institute for Biomedical Research. Dr. Mulligan currently serves on the board of directors of Bausch Health Companies Inc., a public pharmaceutical company. Dr. Mulligan previously served on the board of directors of Biogen Inc., a public biotechnology company. Dr. Mulligan's honors include the MacArthur Foundation Genius Prize, the Rhodes Memorial Award of the American Association for Cancer Research, the ASMB-Amgen Award, and the Nagai Foundation International Prize. Dr. Mulligan received his Ph.D. in Biochemistry from the Stanford University School of Medicine and his B.S. from MIT.
- Douglas Cole
-
Douglas Cole， 他是医学博士。自2015年5月起担任Denali Therapeutics Inc.的董事会成员。他担任Sana Biotechnology, Inc.的董事（2006年8月以来）。他于2001年加入Flagship Ventures公司，在那里他目前担任普通合伙人。加入Flagship公司之前，他曾担任Vertex Pharmaceuticals公司（生物技术公司）的项目执行官、Cytotherapeutics公司（现称为StemCells公司，生物制药公司）的医药董事，以及Ensemble Therapeutics公司（生物制药公司）的首席执行官。他目前任职于9家私人公司的董事会，即Agios Pharmaceuticals公司、Concert Pharmaceuticals公司、Ensemble Therapeutics公司、Receptos公司、Quanterix公司、Selecta Biosciences公司、Avedro公司、 Permeon Biologics公司、Syros Pharmaceuticals公司。他持有达特茅斯学院（Dartmouth College）的英语学士学位（以优异成绩获得），以及Pennsylvania大学 School of Medicine的医学博士学位。
Douglas Cole,joined Flagship in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Foghorn Therapeutics Inc., a public biotechnology company, and on the boards of directors of a number of private companies. Dr. Cole previously served on the boards of directors of Denali Therapeutics Inc. (Denali), a public biotechnology company, and Sigilon Therapeutics, Inc., which was a public biotechnology company during Dr. Cole's service as a director, until its acquisition by Eli Lilly. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College. - Douglas Cole， 他是医学博士。自2015年5月起担任Denali Therapeutics Inc.的董事会成员。他担任Sana Biotechnology, Inc.的董事（2006年8月以来）。他于2001年加入Flagship Ventures公司，在那里他目前担任普通合伙人。加入Flagship公司之前，他曾担任Vertex Pharmaceuticals公司（生物技术公司）的项目执行官、Cytotherapeutics公司（现称为StemCells公司，生物制药公司）的医药董事，以及Ensemble Therapeutics公司（生物制药公司）的首席执行官。他目前任职于9家私人公司的董事会，即Agios Pharmaceuticals公司、Concert Pharmaceuticals公司、Ensemble Therapeutics公司、Receptos公司、Quanterix公司、Selecta Biosciences公司、Avedro公司、 Permeon Biologics公司、Syros Pharmaceuticals公司。他持有达特茅斯学院（Dartmouth College）的英语学士学位（以优异成绩获得），以及Pennsylvania大学 School of Medicine的医学博士学位。
- Douglas Cole,joined Flagship in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Foghorn Therapeutics Inc., a public biotechnology company, and on the boards of directors of a number of private companies. Dr. Cole previously served on the boards of directors of Denali Therapeutics Inc. (Denali), a public biotechnology company, and Sigilon Therapeutics, Inc., which was a public biotechnology company during Dr. Cole's service as a director, until its acquisition by Eli Lilly. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his A.B. in English from Dartmouth College.
- Joshua H. Bilenker
-
Joshua H. Bilenker，他是医学博士。他曾担任公司的创始人，也曾担任总裁兼首席执行官（2013年6月以来），以及董事会的成员（2013年6月以来）。2013年11月以来，他曾一直担任Aisling Capital公司（私人股本公司）的运营合伙人，在那里他曾担任合伙人（从2012年1月到2013年10月）、此前曾担任负责人（从2008年10月到2011年12月）、职员（从2006年4月到2008年9月）。从2004年到2006年，他曾担任the FDA的肿瘤的办公室的医疗官。他曾在Pennsylvania大学的内科医学和医学肿瘤学进行学习，并获得了这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及Princeton大学的英语学士学位。
Joshua H. Bilenker,is a co-founder of Treeline Biosciences, Inc. (Treeline), a privately held biopharmaceutical company, and has served as its Chief Executive Officer since April 2021. Prior to Treeline, he served as Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly, from December 2019 to January 2021, and served as founding Chief Executive Officer of Loxo, which was a public biopharmaceutical company, from June 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC in April 2006 and served there in various capacities, including as an Operating Partner from November 2013 to December 2019. Previously, Dr. Bilenker served as a medical officer in the Office of Oncology Drug Products at the United States Food and Drug Administration from August 2004 to April 2006. Dr. Bilenker previously served on the boards of directors of several public companies, including Gossamer Bio, a public biopharmaceutical company, Loxo, ViewRay, Inc., a public medical technology and device company, T2 Biosystems, Inc., a public medical diagnostics company, and Roka Bioscience, Inc., a molecular diagnostics company that was public during Dr. Bilenker's service as a director. Dr. Bilenker also formerly served on the board of directors of the National Comprehensive Cancer Network Foundation and BioEnterprise. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology and earned board certification in these specialties. Dr. Bilenker received his M.D. from the Johns Hopkins School of Medicine and his A.B. in English from Princeton University. - Joshua H. Bilenker，他是医学博士。他曾担任公司的创始人，也曾担任总裁兼首席执行官（2013年6月以来），以及董事会的成员（2013年6月以来）。2013年11月以来，他曾一直担任Aisling Capital公司（私人股本公司）的运营合伙人，在那里他曾担任合伙人（从2012年1月到2013年10月）、此前曾担任负责人（从2008年10月到2011年12月）、职员（从2006年4月到2008年9月）。从2004年到2006年，他曾担任the FDA的肿瘤的办公室的医疗官。他曾在Pennsylvania大学的内科医学和医学肿瘤学进行学习，并获得了这些专业委员会的认证。他持有The Johns Hopkins School of Medicine的医学博士，以及Princeton大学的英语学士学位。
- Joshua H. Bilenker,is a co-founder of Treeline Biosciences, Inc. (Treeline), a privately held biopharmaceutical company, and has served as its Chief Executive Officer since April 2021. Prior to Treeline, he served as Chief Executive Officer of Loxo Oncology at Lilly, a research and development group of Eli Lilly, from December 2019 to January 2021, and served as founding Chief Executive Officer of Loxo, which was a public biopharmaceutical company, from June 2013 until its acquisition by Eli Lilly in February 2019. Dr. Bilenker joined Aisling Capital LLC in April 2006 and served there in various capacities, including as an Operating Partner from November 2013 to December 2019. Previously, Dr. Bilenker served as a medical officer in the Office of Oncology Drug Products at the United States Food and Drug Administration from August 2004 to April 2006. Dr. Bilenker previously served on the boards of directors of several public companies, including Gossamer Bio, a public biopharmaceutical company, Loxo, ViewRay, Inc., a public medical technology and device company, T2 Biosystems, Inc., a public medical diagnostics company, and Roka Bioscience, Inc., a molecular diagnostics company that was public during Dr. Bilenker's service as a director. Dr. Bilenker also formerly served on the board of directors of the National Comprehensive Cancer Network Foundation and BioEnterprise. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology and earned board certification in these specialties. Dr. Bilenker received his M.D. from the Johns Hopkins School of Medicine and his A.B. in English from Princeton University.
高管简历
中英对照 | 中文 | 英文- Steven D. Harr
Steven D. Harr是Sana的联合创始人，自2018年9月起担任Sana Biotechnology, Inc.总裁兼首席执行官，自2018年10月起担任Sana Biotechnology, Inc.董事会成员。在加入Sana之前，Harr博士曾于2014年4月至2018年3月被新基医药公司（Celgene）收购，在其任职期间曾担任Juno Therapeutics, Inc.（Juno）的首席财务官和企业发展主管，该公司是一家上市生物制药公司。在Juno，Harr博士负责公司的整体财务和运营战略。在加入Juno之前，Harr博士曾在公营跨国投资银行和金融服务公司摩根士丹利担任董事总经理兼生物技术投资银行业务主管，在担任投资银行职务之前，他在摩根士丹利担任首席生物技术研究分析师兼全球医疗保健研究联席主管。Dr. Harr此前曾担任Loxo Oncology, Inc.（LOXO）的董事会成员，该公司在Dr. Harr担任董事期间是一家上市生物制药公司，直到2019年初被礼来公司（礼来）和他共同创立的中国上市细胞治疗公司JW（Cayman）Therapeutics Co. Ltd（JW Therapeutics）收购。哈尔博士是加州大学旧金山分校的内科住院医师。哈尔博士在约翰霍普金斯大学医学院获得医学博士学位，在圣十字学院获得经济学学士学位。
Steven D. Harr,is a co-founder of Sana and has served as Sana Biotechnology, Inc. President and Chief Executive Officer since September 2018 and as a member of Sana Biotechnology, Inc. Board since October 2018. Prior to Sana, Dr. Harr served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, Inc. (Juno), which was a public biopharmaceutical company during his tenure, from April 2014 until its acquisition by Celgene Corporation (Celgene) in March 2018. At Juno, Dr. Harr was responsible for the overall financial and operational strategy of the company. Prior to Juno, Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley, a public multinational investment bank and financial services company, and prior to his investment banking role was the Lead Biotech Research Analyst and Co-head of Global Healthcare Research at Morgan Stanley. Dr. Harr previously served as a member of the boards of directors of Loxo Oncology, Inc. (Loxo), which was a public biopharmaceutical company during Dr. Harr's service as a director, until its acquisition by Eli Lilly and Company (Eli Lilly) in early 2019, and JW (Cayman) Therapeutics Co. Ltd (JW Therapeutics), a public cell therapy company in China that he co-founded. Dr. Harr was a resident in internal medicine at the University of California, San Francisco. Dr. Harr received his M.D. from the Johns Hopkins University School of Medicine and his B.A. in Economics from the College of the Holy Cross.- Steven D. Harr是Sana的联合创始人，自2018年9月起担任Sana Biotechnology, Inc.总裁兼首席执行官，自2018年10月起担任Sana Biotechnology, Inc.董事会成员。在加入Sana之前，Harr博士曾于2014年4月至2018年3月被新基医药公司（Celgene）收购，在其任职期间曾担任Juno Therapeutics, Inc.（Juno）的首席财务官和企业发展主管，该公司是一家上市生物制药公司。在Juno，Harr博士负责公司的整体财务和运营战略。在加入Juno之前，Harr博士曾在公营跨国投资银行和金融服务公司摩根士丹利担任董事总经理兼生物技术投资银行业务主管，在担任投资银行职务之前，他在摩根士丹利担任首席生物技术研究分析师兼全球医疗保健研究联席主管。Dr. Harr此前曾担任Loxo Oncology, Inc.（LOXO）的董事会成员，该公司在Dr. Harr担任董事期间是一家上市生物制药公司，直到2019年初被礼来公司（礼来）和他共同创立的中国上市细胞治疗公司JW（Cayman）Therapeutics Co. Ltd（JW Therapeutics）收购。哈尔博士是加州大学旧金山分校的内科住院医师。哈尔博士在约翰霍普金斯大学医学院获得医学博士学位，在圣十字学院获得经济学学士学位。
- Steven D. Harr,is a co-founder of Sana and has served as Sana Biotechnology, Inc. President and Chief Executive Officer since September 2018 and as a member of Sana Biotechnology, Inc. Board since October 2018. Prior to Sana, Dr. Harr served as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics, Inc. (Juno), which was a public biopharmaceutical company during his tenure, from April 2014 until its acquisition by Celgene Corporation (Celgene) in March 2018. At Juno, Dr. Harr was responsible for the overall financial and operational strategy of the company. Prior to Juno, Dr. Harr was Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley, a public multinational investment bank and financial services company, and prior to his investment banking role was the Lead Biotech Research Analyst and Co-head of Global Healthcare Research at Morgan Stanley. Dr. Harr previously served as a member of the boards of directors of Loxo Oncology, Inc. (Loxo), which was a public biopharmaceutical company during Dr. Harr's service as a director, until its acquisition by Eli Lilly and Company (Eli Lilly) in early 2019, and JW (Cayman) Therapeutics Co. Ltd (JW Therapeutics), a public cell therapy company in China that he co-founded. Dr. Harr was a resident in internal medicine at the University of California, San Francisco. Dr. Harr received his M.D. from the Johns Hopkins University School of Medicine and his B.A. in Economics from the College of the Holy Cross.
- Bernard J. Cassidy
Bernard J. Cassidy，2014年1月以来，他一直担任总法律顾问。加入之前，他曾担任Tessera Technologies公司（半导体封装公司）的多种职务（从2008年11月到2013年7月），包括其执行副总裁、总法律顾问和秘书，以及Tessera Intellectual Property公司的总裁。他曾担任Tumbleweed Communications公司（安全信息和安全文件传输解决方案的供应商）的多种职务（从1999年5月到2008年9月），包括其高级副总裁、总法律顾问和秘书，负责法律、企业发展和人力资源问题。他曾在Wilson Sonsini Goodrich & Rosati公司（专业公司）（从1992年8月到1999年5月），以及Skadden, Arps, Slate, Meagher & Flom公司（从1989年9月到1992年7月）从事法律执业。他于1978年获得新奥尔良Loyola大学的the Jesuit House of Studies的哲学学士学位，于1981年获得Toronto大学的哲学硕士学位，并于1988年获得哈佛法学院（Harvard Law School）的法学博士学位。他也于2004年在斯坦福大学商学院 （ Stanford Graduate School of Business ）完成成长型企业的高管教育项目。
Bernard J. Cassidy has served as general counsel since January 2014. Prior to joining, Mr. Cassidy served in various roles at Tessera Technologies, Inc., a semiconductor packaging company, from November 2008 to July 2013 including as its executive vice president, general counsel and secretary, and as president of Tessera Intellectual Property Corp. He served in various roles at Tumbleweed Communications Corp., a provider of secure messaging and secure file transfer solutions, from May 1999 to September 2008 including as its senior vice president, general counsel and secretary, with responsibility for legal, corporate development, and human resources matters. He practiced law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, from August 1992 to May 1999 and at Skadden, Arps, Slate, Meagher & Flom LLP from September 1989 to July 1992. Mr. Cassidy received a B.A. in Philosophy from the Jesuit House of Studies, Loyola University, New Orleans in 1978 an M.A. in Philosophy from the University of Toronto in 1981 and a J.D. from Harvard Law School in 1988. He also completed the Executive Education Program for Growing Companies at Stanford Graduate School of Business in 2004.- Bernard J. Cassidy，2014年1月以来，他一直担任总法律顾问。加入之前，他曾担任Tessera Technologies公司（半导体封装公司）的多种职务（从2008年11月到2013年7月），包括其执行副总裁、总法律顾问和秘书，以及Tessera Intellectual Property公司的总裁。他曾担任Tumbleweed Communications公司（安全信息和安全文件传输解决方案的供应商）的多种职务（从1999年5月到2008年9月），包括其高级副总裁、总法律顾问和秘书，负责法律、企业发展和人力资源问题。他曾在Wilson Sonsini Goodrich & Rosati公司（专业公司）（从1992年8月到1999年5月），以及Skadden, Arps, Slate, Meagher & Flom公司（从1989年9月到1992年7月）从事法律执业。他于1978年获得新奥尔良Loyola大学的the Jesuit House of Studies的哲学学士学位，于1981年获得Toronto大学的哲学硕士学位，并于1988年获得哈佛法学院（Harvard Law School）的法学博士学位。他也于2004年在斯坦福大学商学院 （ Stanford Graduate School of Business ）完成成长型企业的高管教育项目。
- Bernard J. Cassidy has served as general counsel since January 2014. Prior to joining, Mr. Cassidy served in various roles at Tessera Technologies, Inc., a semiconductor packaging company, from November 2008 to July 2013 including as its executive vice president, general counsel and secretary, and as president of Tessera Intellectual Property Corp. He served in various roles at Tumbleweed Communications Corp., a provider of secure messaging and secure file transfer solutions, from May 1999 to September 2008 including as its senior vice president, general counsel and secretary, with responsibility for legal, corporate development, and human resources matters. He practiced law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, from August 1992 to May 1999 and at Skadden, Arps, Slate, Meagher & Flom LLP from September 1989 to July 1992. Mr. Cassidy received a B.A. in Philosophy from the Jesuit House of Studies, Loyola University, New Orleans in 1978 an M.A. in Philosophy from the University of Toronto in 1981 and a J.D. from Harvard Law School in 1988. He also completed the Executive Education Program for Growing Companies at Stanford Graduate School of Business in 2004.